# Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

> **NCT00073502** · PHASE2 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 43 (—)

## Conditions studied

- Gastroesophageal Adenocarcinoma
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** OSI-7904L

## Key facts

- **NCT ID:** NCT00073502
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2003-10
- **Target enrollment:** 43 (—)
- **Last updated:** 2006-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073502, "Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00073502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*